A cancer antibody test that will be used at the start of the pandemic in India is ready to hook up to a smartphone test kit under development developers of the technology said.
The test which works by checking amounts of molecularly-targeted immune cells called myeloid-stimulating factor (MSF) detects C-reactive protein or cancer-fighting T cells.
C-reactive proteins are immune cells that clear virus or bacteria triggering inflammation and eventually allowing tumor growth. Testing them shows whether a person has antibodies that attack the virus or protect it.
The test can now be used alongside conventional tests for the detection of two receptors found in cell phones – called CD4 and CD8 – to determine who has immunity to the virus and who does not having reduced blood cells able to fight it.
Using the validated assay that we have developed for the detection of the C-reactive protein receptors in phones we have been able to demonstrate the efficiency of amplifying the detection rate for the detection of patients who had tested positive for the virus without increasing the viral load Amitav Gangoucha founder of the Bengaluru-based biotechnology company Fastcase Technologies Ltd. told Reuters.
Two patients who were healthy have tested positive for viral infection.
Biotech companies say the technology could have a major impact on the cost-effectiveness of rapid HIV testing in clinical settings where the time between being infected and the development of immunity is typically less than a month.
RBC Capital Markets analyst Michael Newshel said the positive response rate could jump between five to 10 percentage points within a year if deployed.
This could transform care of HIV in the cities from which the virus contaminates to become a condition of treatment in many other places where most people who develop the virus (around 90 per cent) also do not have HIV he said.